Therapeutic Area: Oncology

Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP

Nijland M, et al.
Blood Advances
April 2025
Authors and Affiliates
Marcel Nijland 1, Djamila E Issa 2, Johanna A A Bult 1, Dries Deeren 3, Gerjo A Velders 4, Marten R Nijziel 5, Yorick Sandberg 6, Vibeke Kj Vergote 7, Margriet Oosterveld 8, Rob Fijnheer 9, Rolf Brouwer 10, Rinske Boersma 11, Kalung Wu 12, Laurens Nieuwenhuizen 13, Joost Sp Vermaat 14, Roel J W van Kampen 15, Wim E Terpstra 16, Sylvia Snauwaert 17, Marjolein Wm van der Poel 18, Eva de Jongh 19, Marc Durian 20, Leonie Strobbe 21, Aart Beeker 22, Alain Pa Gadisseur 23, Roos Van Rijn 24, Otto J Visser 25, Jeanette Doorduijn 26, Tjeerd J F Snijders 27, Matthijs H Silbermann 28, Daphne de Jong 29, Martine E D Chamuleau 30, Rogier Mous 31, Mathilde Jalving 1, Heleen Visser-Wisselaar 32, Sonja Jansen van den Bergh 32, Gerben Jc Zwezerijnen 33, Edwin Bremer 1, Mirian Brink 34, Arjan Diepstra 1, Dana A Chitu 35, Harry R Koene 36, Josée M Zijlstra 37 1University Medical Center Groningen, Groningen, Netherlands. 2Jeroen Bosch hospital, Den Bosch, Netherlands. 3AZ Delta, Roeselare, Belgium. 4Hospital Gelderse Vallei, Ede, Netherlands. 5Catharina Cancer Institute, Eindhoven, Netherlands. 6Maasstad Hospital, Rotterdam, Netherlands. 7UZLeuven, Leuven, Belgium. 8Canisius-Wilhelmina Hospital, Nijmegen, Netherlands. 9Meander Medical Centre, Amersfoort, Netherlands. 10Reinier de Graaf Hospital, Delft, Netherlands. 11Amphia Hospital, Breda, Netherlands. 12ZNA Stuivenberg, Antwerp, Belgium. 13Maxima Medical Center, Veldhoven, Netherlands. 14Leiden University Medical Center, Leiden, Netherlands. 15Zuyerland Medical Center, Sittard-Geleen, Netherlands. 16Olvg, Amsterdam, Netherlands. 17AZ Sint-Jan Hospital Bruges, Bruges, Belgium. 18Maastricht University Medical Center, Maastricht, Netherlands. 19Albert Schweitzer Hospital, Dordrecht, Netherlands. 20ETZ Tilburg, Tilburg, Netherlands. 21Gelre ziekenhuizen, Zutphen, Netherlands. 22Spaarne Gasthuis, Hoofddorp, Netherlands. 23Antwerp University Hospital, Edegem, Belgium. 24Leeuwarden, Netherlands. 25Isala Clinic, Zwolle, Netherlands. 26Erasmus MC, Cancer Institute, Rotterdam, Netherlands. 27Medical Spectrum Twente (MST), Enschede, Netherlands. 28Tergooi Hospital, Hilversum, Netherlands. 29Netherlands Cancer Institute, Amsterdam, Netherlands. 30Amsterdam UMC, Vrije Universtiteit, Cancer Center Amsterdam, Amsterdam, Netherlands. 31University Medical Center Utrecht, Utrecht, Netherlands. 32Erasmus MC Cancer Institute, Rotterdam, Netherlands. 33Amsterdam UMC, location VUMC, Cancer Center Amsterdam, Amsterdam, Netherlands. 34Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands. 35Erasmus MC Rotterdam, The Netherlands, Rotterdam, Netherlands. 36St. Antonius Ziekenhuis, Nieuwegein, Netherlands. 37Amsterdam UMC, Amsterdam, Netherlands.

Project EVOLVE: An international analysis of post-immunotherapy lineage switch, an emergent form of relapse in leukemia

Silbert S, et al.
Blood
April 2025
Authors and Affiliates
Sara Silbert (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Alexander Rankin (Nationwide Children's Hospital, United States) Chloe Hoang (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Alexandra Semchenkova (Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Russian Federation) Regina Myers (Children's Hospital of Philadelphia, United States) Elena Zerkalenkova (Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Russian Federation) Hao-Wei Wang (National Institutes of Health, United States) Alexandra Kovach (Children's Hospital Los Angeles, United States) Constance Yuan (NCI/NIH, United States) Dana Delgado Colon (NCI/NIH, United States) Loic Vasseur (Hôpital Saint Louis, France) Alex Bataller (The University of Texas MD Anderson Cancer Center, United States) Samuel John (Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, United States) Kaylyn Utley Lyons (Children's Hospital Colorado, University of Colorado School of Medicine, Denver CO, United States) Barbara Friedes (Children's Hospital of Philadelphia, United States) Anna Alonso-Saladrigues (Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu. Barcelona. Spain; Institut de Recerca Sant Joan de Déu, Barcelona, Spain; Medicine and Surgery School. University of Barcelona. Barcelona, Spain., Spain) Hisham Abdel-Azim (Loma Linda University school of Medicine, Cancer Center, Children Hospital and Medical Center, United States) Estelle Balducci (Hôpital Necker-Enfants Malades, APHP, France) Ahmed Aljudi (Children's Healthcare of Atlanta, United States) Marie Balsat (Hôpital Lyon sud, Pierre-Bénite, France) D. Biery (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Aghiad Chamdin (Children's hospital of Michigan/Central Michigan University, United States) Bill Chang (OHSU, United States) Raymund Cuevo (Inova Schar Cancer Institute, United States) Barbara De Moerloose (Ghent University Hospital, Belgium) David Dickens (Stead Family Children's Hospital University of Iowa, United States) Ulrich Duffner (Pediatric Bone Marrow Transplantation & Cellular Therapy, Corewell Health Helen DeVos Children's Hospital, 100 Michigan Street NE Grand Rapids, MI 49503, United States) Nicolas Duployez (CHU Lille, France) Firas El Chaer (Division of Hematology and Oncology, Department of Medicine, The University of Virginia, United States) Michelle Elliott (Mayo Clinic, United States) Gabriele Escherich (University hospital Hamburg Eppendorf, Germany) Sneha Fernandes (Great Ormond Street Hospital for Children, London, United Kingdom) Mandi Fitzjohn (Children's Hospital Colorado, University of Colorado School of Medicine, Denver CO, United States) Zhubin Gahvari (University of Wisconsin School of Medicine and Public Health, United States) Stephan Grupp (Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Perelman School ofMedicine, University of Pennsylvania, Philadelphia, PA, USA, United States) Rui Rochelle He (Department of Pathology, Inova Fairfax Medical Campus. Inova Health System, Falls Church, VA 22042, United States) Cynthia Harrison (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States) Christopher Hergott (Brigham and Women's Hospital, United States) Emily Hsieh (Children's Hospital Los Angeles, United States) Annette Kim (University of Michigan, United States) Dennis Kuo (University of California San Diego, United States) Daniel Larson (Mayo Clinic, United States) Benjamin Lee (UC Irvine Health, United States) Thibaut Leguay (Hopital du Haut-Lévèque, France) R. Lindsley (Dana-Farber Cancer Institute, United States) Abhishek Mangaonkar (Mayo Clinic, United States) Kerstin Mezger (Clinic of Paediatric Haematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, Germany) Holly Pacenta (Cook Children's Medical Center, United States) Jing Pan (Beijing GoBroad Hospital, China) Marlie Provost (HCA HealthONE - Rocky Mountain Hospital for Children, United States) Latika Puri (Loma Linda University Children' Hospitalpital, United States) Sunil Raikar (Emory University, United States) Armando Martinez (National Institutes of Health, United States) Isabella Bristol (National Institutes of Health, United States) Kyle Murphy (National Institutes of Health, United States) Lauren Reiman (Children's Hospital Los Angeles, United States) Michele Redell (Texas Children's Hospital, Baylor College of Medicine, United States) Kelly Reed (University of Virginia School of Nursing, United States) Gabrielle Roth Guepin (Chu nancy, France) Jeremy Rubinstein (Cincinnati Children's Hospital Medical Center, United States) Süreyya Savaşan (Children's Hospital of Michigan, United States) Kristian Schafernak (Phoenix Children's Hospital, United States) Alexandra McLean Stevens (Texas Children's Hospital Downloaded from http://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2024026655/2367646/blood.2024026655.pdf by guest on 11 April 2025 Baylor College of Medicine, United States) Aimee Talleur (St. Jude Children's Research Hospital, United States) Naomi Torres Carapia (Children's Hospital Los Angeles, United States) Jacques Vargaftig (Institut Curie, France) Anant Vatsayan (Children's National Hospital, United States) Matthias Wölfl (University Hospital Wurzburg, Germany) Liping Zhao (State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China) Susana Rives (Leukemia and Lymphoma Department. Pediatric Cancer Center Barcelona (PCCB), Hospital Sant Joan de Déu Barcelona, Spain) Vanessa Fabrizio (University of Colorado Anschutz Medical Campus, United States) Koji Sasaki (The University of Texas MD Anderson Cancer Center, United States) Ibrahim Aldoss (City of Hope National Medical Center, United States) Nicolas Boissel (Hopital Saint-Louis, AP-HP, France) Susan Rheingold (The Children's Hospital of Philadelphia, United States) Kara Davis (Stanford University, United States) Sara Ghorashian (University College London Great Ormond Street Institute of Child Health, United Kingdom) Elad Jacoby (Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel, Israel) Alexander Popov (National Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation) Adam Lamble (Seattle Children's Hospital, United States) Nirali Shah (Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), United States)

A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma

Lopedote P, et al.
British Journal of Haematology
April 2025
Authors and Affiliates
Paolo Lopedote1 Geoffrey Shouse1 Sandrine Puverel1 Alexandra Muir1 Carly Roleder1 Peter Sportelli2 Hari Miskin2 Lu Chen1 Tycel J. Phillips1 Alexey V. Danilov1 1City of Hope National Medical Center, Duarte, California, USA 2TG Therapeutics Inc., Morrisville, North Carolina, USA

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma

Shah N, et al.
Journal of Clinical Oncology
March 2025
Authors and Affiliates
Nirav N. Shah, MD, MS1 ; Alfredo S. Colina, BA2 ; Bryon D. Johnson, PhD1; Aniko Szabo, PhD3; Fateeha Furqan, MD1; Tyce Kearl, MD, PhD1 ; Dina Schneider, PhD4 ; Marlenny Vargas-Cortes, BS5 ; Jessica L. Schmeling, BS5 ; Michael B. Dwinell, PhD2; Katie Palen, BS1; Walter Longo, MD1; Peiman Hematti, MD1 ; Anthony E. Zamora, PhD2 ; Parameswaran Hari, MD, MS1 ; Daniel Bucklan, MD6; Ashley Cunningham, MD7; Mehdi Hamadani, MD1 ; and Timothy S. Fenske, MD1 1BMT & Cellular Therapy Program, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI 2Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, WI 3Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI 4Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD 5Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 6Department of Radiology, Medical College of Wisconsin, Milwaukee,WI 7Department of Pathology, Medical College of Wisconsin, Milwaukee, WI

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia

Brown J, et al.
nejm
February 2025
Authors and Affiliates
J.R. Brown,1 J.F. Seymour,2,3 W. Jurczak,4 A. Aw,5 M. Wach,6 A. Illes,7 A. Tedeschi,8 C. Owen,9 A. Skarbnik,10 D. Lysak,11 K.-S. Eom,12 M. Šimkovič,13 M.A. Pavlovsky,14 A.P. Kater,15 B. Eichhorst,16 K. Miller,17 V. Munugalavadla,17 T. Yu,17 M. de Borja,18 and P. Ghia,19,20 for the AMPLIFY investigators* 1 Dana–Farber Cancer Institute, Boston; 2 Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; 3 Royal Melbourne Hospital, University of Melbourne, Melbourne, VIC, Australia; 4 Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland; 5 University of Ottawa, Ottawa; 6 Medical University of Lublin, Lublin, Poland; 7 Faculty of Medicine, Division of Hematology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary; 8 ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan; 9 University of Calgary, Calgary, AB, Canada; 10 Novant Health Cancer Institute, Charlotte, NC; 11 Fakultní Nemocnice Plzen, Pilsen, Czech Republic; 12 Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, Seoul, South Korea; 13 4th Department of Internal Medicine–Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University, Hradec Kralove, Czech Republic; 14 FUNDALEU, Clinical Research Center, Buenos Aires; 15 Amsterdam University Medical Centers, University of Amsterdam, Amsterdam; 16 University Hospital Cologne, Cologne, Germany; 17 AstraZeneca, South San Francisco, CA; 18 AstraZeneca, Mississauga, ON, Canada; 19 Università Vita-Salute San Raffaele, Milan; 20 IRCCS Ospedale San Raffaele, Milan.

Hyper-CVADand Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Kantarjian H, et al.
Am J Hematol
January 2025
Authors and Affiliates
Hagop Kantarjian | Nicholas J. Short | Nitin Jain | Fadi G. Haddad | Tapan Kadia | Musa Yilmaz | Alessandra Ferrajoli | Koji Sasaki | Yesid Alvarado | Naveen Pemmaraju | Jayastu Senapati | Rebecca Garris | Farhad Ravandi | Elias Jabbour Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia

Roddie C, et al.
nejm
November 2024
Authors and Affiliates
Claire Roddie, M.D., Karamjeet S. Sandhu, M.D., Eleni Tholouli, M.D., Aaron C. Logan, M.D., Paul Shaughnessy, M.D., Pere Barba, M.D., Armin Ghobadi, M.D., Manuel Guerreiro, M.D., Deborah Yallop, M.D., Mehrdad Abedi, M.D., Jeremy M. Pantin, M.D., Jean A. Yared, M.D., Amer M. Beitinjaneh, M.D., Sridhar Chaganti, M.D., Katharine Hodby, M.D., Tobias Menne, M.D., Martha L. Arellano, M.D., Ram Malladi, M.D., Bijal D. Shah, M.D., Luke Mountjoy, M.D., Kristen M. O’Dwyer, M.D., Karl S. Peggs, M.D., Pierre Lao‑Sirieix, Ph.D., Yiyun Zhang, Ph.D., Wolfram Brugger, M.D., Edgar Braendle, M.D., Martin Pule, M.D., Michael R. Bishop, M.D., Daniel J. DeAngelo, M.D., Jae H. Park, M.D., and Elias Jabbour, M.D. the Cancer Institute, University College London (C.R., K.S.P., M.P.), University College London Hospitals NHS Foundation Trust (C.R.), King’s College Hospital NHS Foundation Trust (D.Y.), and Autolus Therapeutics (P.L.-S., Y.Z., W.B., E.B., M.P.), London, Manchester Royal Infirmary, Manchester (E.T.), University Hospitals Birmingham NHS Foundation Trust, Birmingham (S.C.), University Hospitals Bristol NHS Foundation Trust, Bristol (K.H.), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle (T.M.), and Cambridge University Hospitals NHS Foundation Trust, Cambridge (R.M.) — all in the United Kingdom; City of Hope National Medical Center, Duarte (K.S.S.), the Hematology, Blood and Marrow Transplant, and Cellular Therapy Program, University of California, San Francisco, San Francisco (A.C.L.), and UC Davis Medical Center, Sacramento (M.A.) — all in California; the Sarah Cannon Transplant and Cellular Therapy Program, Methodist Hospital, San Antonio (P.S.), and the University of Texas M.D. Anderson Cancer Center, Houston (E.J.) — both in Texas; Hospital Universitari Vall d’Hebron–Universitat Autónoma de Barcelona, Barcelona (P.B.), and Hospital Universitari i Politècnic La Fe, Valencia (M.G.) — both in Spain; Washington University School of Medicine, St. Louis (A.G.); the Sarah Cannon Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, Nashville (J.M.P.); the University of Maryland Medical Center, Baltimore (J.A.Y.); Miller School of Medicine, University of Miami, Miami (A.M.B.), and Moffitt Cancer Center, Tampa (B.D.S.) — both in Florida; Winship Cancer Institute of Emory University, Atlanta (M.L.A.); Colorado Blood Cancer Institute, Denver (L.M.); the University of Rochester Medical Center, Rochester (K.M.O.), and Memorial Sloan Kettering Cancer Center, New York (J.H.P.) — both in New York; the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago (M.R.B.); and Dana–Farber Cancer Institute, Boston (D.J.D.).

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Al-Sawaf O, et al.
Blood
October 2024
Authors and Affiliates
Othman Al-Sawaf,1 Sandra Robrecht,1 Can Zhang,1 Stefano Olivieri,2 Yi Meng Chang,3 Anna Maria Fink,1 Eugen Tausch,4 Christof Schneider,4 Matthias Ritgen,5 Karl-Anton Kreuzer,1 Liliya Sivchev,6 Carsten Utoft Niemann,7 Anthony Schwarer,8 Javier Loscertales,9 Robert Weinkove,10,11 Dirk Strumberg,12 Allanah Kilfoyle,13 Beenish S. Manzoor,14 Dureshahwar Jawaid,14 Nnadozie Emechebe,14 Jacob Devine,15 Michelle Boyer,16 Eva D. Runkel,14 Barbara Eichhorst,1 Stephan Stilgenbauer,4 Yanwen Jiang,15 Michael Hallek,1 and Kirsten Fischer1 1Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany; 2F. Hoffmann-La Roche Ltd, Basel, Switzerland; 3F. Hoffmann- La Roche Ltd, Mississauga, ON, Canada; 4Division of CLL, Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany; 5Universitätsklinikum Schleswig Holstein, Kiel, Germany; 6Multiprofile Hospital for Active Treatment Pazardjik, Pazardzhik, Bulgaria; 7Rigshospitalet, Copenhagen, Denmark; 8Box Hill Hospital, Box Hill, VIC, Australia; 9Hospital De La Princesa, Madrid, Spain; 10Te Rerenga Ora Wellington Blood and Cancer Centre, Te Whatu Ora Health New Zealand Capital, Wellington, New Zealand; 11Cancer Immunotherapy Program, Malaghan Institute of Medical Research, Wellington, New Zealand; 12Evangelisches Krankenhaus Herne, Herne, Germany; 13Palmerston North Hospital, Palmerston North, New Zealand; 14AbbVie Inc, Chicago, IL; 15Genentech Inc, South San Francisco, CA; and 16F. Hoffmann-La Roche Ltd, Welwyn, United Kingdom

Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation

Kumar A, et al.
Blood
October 2024
Authors and Affiliates
Anita Kumar, MD1, Jacob Soumerai, MD2, Jeremy S. Abramson, MD2, Jeffrey A. Barnes, MD2, PhD, Philip Caron, MD1, Shalini Chhabra, MD1, Maria Chabowska, BSc1, Ahmet Dogan, MD1, PhD1, Lorenzo Falchi, MD1, Clare Grieve, MPH1, Julie E. Haydu, MD PhD2, Patrick Connor Johnson, MD2, Ashlee Joseph BS1, Hailey E. Kelly2, Alyssa Labarre1, Jennifer Kimberly Lue, MD1, Rosalba Martignetti2, Joanna Mi, NP1, Alison Moskowitz, MD1, Colette Owens, MD1, Sean Plummer2, Madeline Puccio2, Gilles Salles, MD, PhD1, Venkatraman Seshan, PhD1, Elizabeth Simkins2, Natalie Slupe1, Honglei Zhang, MD1, and Andrew D. Zelenetz, MD, PhD1 1. Memorial-Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA 2. Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, USA

Measurable Residual Disease Testing Following Non-Intensive Chemoimmunotherapy Is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Chang J, et al.
Clinical Lymphoma Myeloma & Leukemia
October 2024
Authors and Affiliates
Julie E. Chang MD,1 Danielle McQuinn MD, 1 Meredith Hyun MS,2 KyungMann Kim PhD,2,3 Vaishalee P Kenkre MD,1 Saurabh A. Rajguru MD,1 Priyanka A. Pophali MD,1 Mariah Endres,3 Mitch Howard,3 Tim Wassenaar MD, MS,4 Ruth Callaway Warren MD,5 Ryan J Mattison MD,1 Kari B Wisinski MD1 Christopher D Fletcher MD1 1Department of Medicine, University of Wisconsin School of Medicine and Public Health 2Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health 3University of Wisconsin Carbone Cancer Center, Madison, WI 4ProHealth Care, Waukesha, WI 5Green Bay Oncology, St. Vincent Regional Cancer Center, Green Bay, WI